CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Operating activities
Net loss	$ (63,195)	$ (58,579)	$ (24,390)	$ (31,610)	$ (121,774)	$ (56,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,350		1,295		2,802	2,613
Equity-based compensation					7,974	7,896
Change in fair value of warrants	8,836		8,490		2,795	21,666
Debt extinguishment loss					13,734
Issuance of common warrants					9,006
Change in fair value of derivative liability	30,658				55,181
Change in fair value of asset purchase agreement liability						(1,878)
Realized and unrealized gain on short term investments					(1,160)	(254)
Equity method investment loss					74	81
Asset retirement obligation accretion					52	32
Amortization of debt discount					4,275	2,950
Changes in operating assets and liabilities:
Accounts receivable					1,064	84
Other current assets					(918)	24
Other assets					67	(53)
Accounts payable					752	754
Deferred revenue					65	(82)
Accrued expenses and other liabilities					(120)	2,365
Operating lease right-of-use assets and liabilities					428	523
Net cash used in operating activities					(25,703)	(19,279)
Investing activities
Purchases of network assets, property, and equipment					(57)	(181)
Purchase of internal use software					(200)	(262)
Purchase of marketable securities					(132,141)	(26,144)
Sale and maturity of marketable securities					56,900	7,000
Payment for asset purchase agreement liability						(2,732)
Net cash used in investing activities					(75,498)	(22,319)
Financing activities
Proceeds from 2028 senior convertible notes					190,000
Repayment of 2026 senior secured notes					(70,000)
Payments towards debt issuance cost					(1,517)
Payments towards debt					(56)	(55)
Proceeds from exercise of common warrants					582	21,036
Redemption of non-controlling interests						40
Proceeds from exercise of common stock options					1,422	1,650
Net cash provided by financing activities					120,431	22,671
Effect of exchange rates on cash and cash equivalents					306	22
Net increase (decrease) in cash and cash equivalents					19,536	(18,905)
Cash and cash equivalents at beginning of period		$ 39,330		$ 81,878	39,330	81,878	$ 81,878
Cash and cash equivalents at end of period	$ 58,866		$ 62,973		58,866	62,973	$ 39,330
Non-cash investing and financing information and supplemental disclosures
Capital expenditure included in Accrued expenses and other current liabilities					22	156
Interest paid in shares of common stock						1,867
Interest paid in cash					$ 4,244	$ 1,750